TMO · Company KPIs
Thermo Fisher Scientific (TMO) KPIs
Organic revenue growth, GAAP operating margin, Remaining performance obligations, RPO expected within 12 months (share), GAAP net margin (attributable to Thermo Fisher). As reported in SEC filings, with the source document for each figure.
Organic revenue growth
6% for the period ended Sep 26, 2026
The documents read for this page do not quote a definition of this measure.
| Period ended | Figure | Source |
|---|---|---|
| Sep 26, 2026 | 6% | 5, respectively. Organic revenue growth Three months ended September 26, 2026 Revenue growth 9 % Acquisitions/divestitures 3 % Currency translation 0 % Organic revenue growth (non-GAAP measure) 6 %8-K filed 2026-10-21 |
| Jun 27, 2026 | 5% | 5, respectively. Organic revenue growth Three months ended June 27, 2026 Revenue growth 10 % Acquisitions 5 % Currency translation 1 % Organic revenue growth (non-GAAP measure) 5 %8-K filed 2026-07-23 |
| Mar 28, 2026 | 1% | 5, respectively. Organic revenue growth Three months ended March 28, 2026 Revenue growth 6 % Acquisitions 3 % Currency translation 2 % Organic revenue growth (non-GAAP measure) 1 %8-K filed 2026-04-23 |
| Dec 31, 2025 | 3% | 4, respectively. Organic revenue growth Three months ended December 31, 2025 Revenue growth 7 % Acquisitions 2 % Currency translation 2 % Organic revenue growth (non-GAAP measure) 3 %8-K filed 2026-01-29 |
| Sep 27, 2025 | 3% | 4, respectively. Organic revenue growth Three months ended September 27, 2025 Revenue growth 5 % Acquisitions 1 % Currency translation 1 % Organic revenue growth (non-GAAP measure) 3 %8-K filed 2025-10-22 |
| Jun 28, 2025 | 2% | 4, respectively. Organic revenue growth Three months ended June 28, 2025 Revenue growth 3 % Acquisitions 0 % Currency translation 1 % Organic revenue growth (non-GAAP measure) 2 %8-K filed 2025-07-23 |
| Mar 29, 2025 | 1% | 4, respectively. Organic revenue growth Three months ended March 29, 2025 Revenue growth 0 % Acquisitions 0 % Currency translation -1 % Organic revenue growth (non-GAAP measure) 1 %8-K filed 2025-04-23 |
| Dec 31, 2024 | 4% | Organic and Core organic revenue growth Three months ended December 31, 2024 Revenue growth 5 % Acquisitions 1 % Currency translation 0 % Organic revenue growth (non-GAAP measure) 4 %8-K filed 2025-01-30 |
GAAP operating margin
18.6% for the period ended Sep 26, 2026
The documents read for this page do not quote a definition of this measure.
| Period ended | Figure | Source |
|---|---|---|
| Sep 26, 2026 | 18.6% | adjusted operating margin GAAP operating income $ 2,263 18.6 % $ 1,941 17.4 %8-K filed 2026-10-21 |
| Jun 27, 2026 | 17.4% | adjusted operating margin GAAP operating income $ 2,087 17.4 % $ 1,834 16.9 %8-K filed 2026-07-23 |
| Mar 28, 2026 | 16.9% | adjusted operating margin GAAP operating income $ 1,863 16.9 % $ 1,716 16.6 %8-K filed 2026-04-23 |
| Dec 31, 2025 | 18.5% | adjusted operating margin GAAP operating income $ 2,255 18.5 % $ 2,016 17.7 %8-K filed 2026-01-29 |
| Sep 27, 2025 | 17.4% | adjusted operating margin GAAP operating income $ 1,941 17.4 % $ 1,838 17.3 %8-K filed 2025-10-22 |
| Jun 28, 2025 | 16.9% | adjusted operating margin GAAP operating income $ 1,834 16.9 % $ 1,820 17.3 %8-K filed 2025-07-23 |
| Mar 29, 2025 | 16.6% | adjusted operating margin GAAP operating income $ 1,716 16.6 % $ 1,663 16.1 %8-K filed 2025-04-23 |
| Dec 31, 2024 | 17.7% | adjusted operating margin GAAP operating income $ 2,016 17.7 % $ 1,854 17.0 %8-K filed 2025-01-30 |
Remaining performance obligations
$29.87B for the period ended Sep 26, 2026
The documents read for this page do not quote a definition of this measure.
| Period ended | Figure | Source |
|---|---|---|
| Sep 26, 2026 | $29.87B | aggregate amount of the transaction price allocated to the remaining performance obligations for all open customer contracts as of September 26, 2026, was $ 29.87 billion. The company will recognize revenues fo10-Q filed 2026-10-30 |
| Jun 27, 2026 | $29.7B | aggregate amount of the transaction price allocated to the remaining performance obligations for all open customer contracts as of June 27, 2026, was $ 29.70 billion. The company will recognize revenues fo10-Q filed 2026-07-31 |
| Mar 28, 2026 | $29.41B | aggregate amount of the transaction price allocated to the remaining performance obligations for all open customer contracts as of March 28, 2026, was $ 29.41 billion. The company will recognize revenues fo10-Q filed 2026-05-01 |
| Dec 31, 2025 | $27.92B | aggregate amount of the transaction price allocated to the remaining performance obligations for all open customer contracts as of December 31, 2025 was $ 27.92 billion. The company will recognize revenues fo10-K filed 2026-02-26 |
| Sep 27, 2025 | $26.46B | aggregate amount of the transaction price allocated to the remaining performance obligations for all open customer contracts as of September 27, 2025, was $ 26.46 billion. The company will recognize revenues fo10-Q filed 2025-10-31 |
| Jun 28, 2025 | $25.04B | aggregate amount of the transaction price allocated to the remaining performance obligations for all open customer contracts as of June 28, 2025, was $ 25.04 billion. The company will recognize revenues fo10-Q filed 2025-08-01 |
| Mar 29, 2025 | $24.54B | aggregate amount of the transaction price allocated to the remaining performance obligations for all open customer contracts as of March 29, 2025, was $ 24.54 billion. The company will recognize revenues fo10-Q filed 2025-05-02 |
| Dec 31, 2024 | $24.61B | aggregate amount of the transaction price allocated to the remaining performance obligations for all open customer contracts as of December 31, 2024 was $ 24.61 billion. The company will recognize revenues fo10-K filed 2025-02-20 |
GAAP net margin (attributable to Thermo Fisher)
14.2% for the period ended Sep 26, 2026
The documents read for this page do not quote a definition of this measure.
| Period ended | Figure | Source |
|---|---|---|
| Sep 26, 2026 | 14.2% | Three months ended September 26, % of September 27, % of (Dollars in millions except per share amounts) 2026 … Net income attributable to Thermo Fisher Scientific Inc. $ 1,721 14.2 %8-K filed 2026-10-21 |
| Jun 27, 2026 | 14.5% | Three months ended June 27, % of June 28, % of (Dollars in millions except per share amounts) 2026 … Net income attributable to Thermo Fisher Scientific Inc. $ 1,736 14.5 %8-K filed 2026-07-23 |
| Mar 28, 2026 | 15% | Three months ended March 28, % of March 29, % of (Dollars in millions except per share amounts) 2026 … Net income attributable to Thermo Fisher Scientific Inc. $ 1,651 15.0 %8-K filed 2026-04-23 |
| Dec 31, 2025 | 16.1% | Three months ended December 31, % of December 31, % of (Dollars in millions except per share amounts) 2025 … Net income attributable to Thermo Fisher Scientific Inc. $ 1,964 16.1 %8-K filed 2026-01-29 |
| Sep 27, 2025 | 14.5% | Three months ended September 27, % of September 28, % of (Dollars in millions except per share amounts) 2025 … Net income attributable to Thermo Fisher Scientific Inc. $ 1,616 14.5 %8-K filed 2025-10-22 |
| Jun 28, 2025 | 14.9% | Three months ended June 28, % of June 29, % of (Dollars in millions except per share amounts) 2025 … Net income attributable to Thermo Fisher Scientific Inc. $ 1,617 14.9 %8-K filed 2025-07-23 |
| Mar 29, 2025 | 14.5% | Three months ended March 29, % of March 30, % of (Dollars in millions except per share amounts) 2025 … Net income attributable to Thermo Fisher Scientific Inc. $ 1,507 14.5 %8-K filed 2025-04-23 |
| Dec 31, 2024 | 16.1% | Three months ended December 31, % of December 31, % of (Dollars in millions except per share amounts) 2024 … Net income attributable to Thermo Fisher Scientific Inc. $ 1,830 16.1 %8-K filed 2025-01-30 |
Reading notes
Figures are shown as first reported. If a later filing prints a different figure for the same period, both appear. A figure marked ≈ or shown in words is how the company itself states it, not an estimate of ours. Companies change definitions over time, so compare periods with the quoted definition in mind. Periods that failed our checks are left out, so gaps are expected.
This page shows the latest 8 quarters of each quarterly metric and the latest 5 fiscal years of each annual one.